![Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-074325/F6.large.jpg)
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
![Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults | India News - The Indian Express Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults | India News - The Indian Express](https://images.indianexpress.com/2023/01/covovax.jpg?w=414)
Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults | India News - The Indian Express
![Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ... Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7113e2_JJBoosterVE_IMAGE_29March22_1200x675.jpg?_=89755)
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/attachment/b7470a81-2935-4740-9fb4-c532d912c682/gr1_lrg.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 | Nature Communications Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-29301-9/MediaObjects/41467_2022_29301_Fig1_HTML.png)
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 | Nature Communications
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/62ba4745-8f48-4fd3-a2fb-4d864c9277e3/gr5_lrg.jpg)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_754645_16903578774359511.jpg)
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
![Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/asset/3b4eb078-d7dd-4a37-98ea-553c444f2a49/gr1.jpg)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
![Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/70ac421e-169c-4581-b03c-4ee839310ea2/gr1.jpg)
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases
SII seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults, ET HealthWorld
EU Medicines Agency on X: "‼️ EMA & @ECDC_EU share their recommendations on the possibility of using 2 different #COVID19vaccines, either for the 1st and 2nd doses of a primary course, or
![Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine? Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_739736_16771590842258916.jpg)
Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?
![Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/10/14/2021.10.14.21264981/F1.large.jpg)
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv
![Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study - Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study -](https://www.thelancet.com/cms/asset/9d78c591-56a3-4f67-bb91-52f440d63dcd/gr1.jpg)
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study -
![Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2021/10/shutterstock_1901384401-1.jpg)